Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds.
Forty years after the discovery of the anticancer effects of cisplatin, scientists are still pursuing the development of platinum complexes with improved properties regarding side effects and resistance, which are two main problems in cisplatin treatment. Among these compounds, trans-configured platinum complexes with oxime ligands emerged as a new class with features distinct from those of established anticancer agents, including different DNA binding behavior, increased cellular accumulation, and a different pattern of protein interaction. We report herein on the reactivity with biomolecules of three novel pairs of cis- and trans-configured acetone oxime platinum(II) complexes and one pair of 3-pentanone oxime platinum(II) complexes. Cellular accumulation experiments and in vitro DNA platination studies were performed and platinum contents were determined by inductively coupled plasma mass spectrometry. The trans-configured complexes were accumulated in SW480 cells in up to 100 times higher amounts than cisplatin and up to 50 times higher amounts than their cis-configured counterparts; r                         (b) values (number of platinum atoms per nucleotide) were more than tenfold increased in cells treated with trans complexes compared with cells treated with cisplatin. The interaction of the complexes with DNA was studied in cell-free experiments with plasmid DNA (pUC19), in capillary zone electrophoresis with the DNA model 2-deoxyguanosine 5'-monophosphate, and in in vitro experiments showing the degree of DNA damage in the comet assay. Whereas incubation with cis compounds did not induce degradation of DNA, the trans complexes led to pronounced strand cleavage.
Institute of Inorganic Chemistry, University of Vienna, Austria.
Caroline
C
Bartel
Anna K
AK
Bytzek
Yulia Yu
YY
Scaffidi-Domianello
Gerlinde
G
Grabmann
Michael A
MA
Jakupec
Christian G
CG
Hartinger
Mathea Sophia
MS
Galanski
Bernhard K
BK
Keppler
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000378:metabolism / Q000493:pharmacokinetics*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000737:chemistry / Q000493:pharmacokinetics*; D004247:DNA / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D009944:Organoplatinum Compounds / Q000737:chemistry* / Q000145:classification / Q000493:pharmacokinetics*; D010091:Oximes / Q000737:chemistry* / Q000493:pharmacokinetics
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D010091:Oximes; D004247:DNA; D002945:Cisplatin